NovaBay Pharmaceuticals, Inc. Logo

NovaBay Pharmaceuticals, Inc.

NBY

(1.2)
Stock Price

0,53 USD

-271.69% ROA

-1030.19% ROE

-0.07x PER

Market Cap.

3.340.346,00 USD

-325.77% DER

0% Yield

-90.36% NPM

NovaBay Pharmaceuticals, Inc. Stock Analysis

NovaBay Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

NovaBay Pharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.12x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (36%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROE

Negative ROE (-79.57%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-61.78%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-1), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

NovaBay Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

NovaBay Pharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

NovaBay Pharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

NovaBay Pharmaceuticals, Inc. Revenue
Year Revenue Growth
2003 0
2004 0 0%
2005 0 0%
2006 1.533.000 100%
2007 5.913.000 74.07%
2008 6.722.000 12.04%
2009 15.684.000 57.14%
2010 9.754.000 -60.8%
2011 11.019.000 11.48%
2012 6.947.000 -58.62%
2013 3.477.000 -99.8%
2014 1.054.000 -229.89%
2015 4.381.000 75.94%
2016 11.897.000 63.18%
2017 18.230.000 34.74%
2018 12.508.000 -45.75%
2019 6.599.000 -89.54%
2020 9.934.000 33.57%
2021 8.421.000 -17.97%
2022 14.404.000 41.54%
2023 13.020.000 -10.63%
2023 14.726.000 11.58%
2024 9.600.000 -53.4%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

NovaBay Pharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2003 270.000
2004 0 0%
2005 1.952.000 100%
2006 4.087.000 52.24%
2007 7.421.000 44.93%
2008 9.595.000 22.66%
2009 7.337.000 -30.78%
2010 8.616.000 14.84%
2011 9.911.000 13.07%
2012 9.275.000 -6.86%
2013 12.461.000 25.57%
2014 9.511.000 -31.02%
2015 6.045.000 -57.34%
2016 1.371.000 -340.92%
2017 410.000 -234.39%
2018 259.000 -58.3%
2019 184.000 -40.76%
2020 285.000 35.44%
2021 44.000 -547.73%
2022 174.000 74.71%
2023 44.000 -295.45%
2023 68.000 35.29%
2024 36.000 -88.89%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

NovaBay Pharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 4.368.000 100%
2008 5.636.000 22.5%
2009 5.607.000 -0.52%
2010 5.654.000 0.83%
2011 5.429.000 -4.14%
2012 5.981.000 9.23%
2013 6.340.000 5.66%
2014 7.935.000 20.1%
2015 18.089.000 56.13%
2016 7.235.000 -150.02%
2017 8.636.000 16.22%
2018 5.828.000 -48.18%
2019 5.310.000 -9.76%
2020 5.932.000 10.49%
2021 7.240.000 18.07%
2022 7.489.000 3.32%
2023 4.912.000 -52.46%
2023 6.330.000 22.4%
2024 6.468.000 2.13%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

NovaBay Pharmaceuticals, Inc. EBITDA
Year EBITDA Growth
2003 -929.000
2004 -2.804.000 66.87%
2005 -3.627.000 22.69%
2006 -5.692.000 36.28%
2007 -6.181.000 7.91%
2008 -8.602.000 28.14%
2009 3.149.000 373.17%
2010 -4.347.000 172.44%
2011 -3.134.000 -38.7%
2012 -9.407.000 66.68%
2013 -14.617.000 35.64%
2014 -18.310.000 20.17%
2015 -22.999.000 20.39%
2016 -8.769.000 -162.28%
2017 -7.115.000 -23.25%
2018 -8.916.000 20.2%
2019 -10.508.000 15.15%
2020 -1.162.000 -804.3%
2021 -13.358.000 91.3%
2022 -4.545.000 -193.91%
2023 -4.464.000 -1.81%
2023 -4.800.000 7%
2024 -4.168.000 -15.16%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

NovaBay Pharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
2003 0
2004 0 0%
2005 0 0%
2006 1.533.000 100%
2007 5.913.000 74.07%
2008 6.722.000 12.04%
2009 15.684.000 57.14%
2010 9.754.000 -60.8%
2011 11.019.000 11.48%
2012 6.939.000 -58.8%
2013 3.315.000 -109.32%
2014 568.000 -483.63%
2015 3.120.000 81.79%
2016 9.433.000 66.92%
2017 15.446.000 38.93%
2018 11.005.000 -40.35%
2019 4.861.000 -126.39%
2020 5.964.000 18.49%
2021 5.645.000 -5.65%
2022 7.781.000 27.45%
2023 7.352.000 -5.84%
2023 7.895.000 6.88%
2024 6.368.000 -23.98%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

NovaBay Pharmaceuticals, Inc. Net Profit
Year Net Profit Growth
2003 -977.000
2004 -2.804.000 65.16%
2005 -3.463.000 19.03%
2006 -5.286.000 34.49%
2007 -5.400.000 2.11%
2008 -8.114.000 33.45%
2009 2.697.000 400.85%
2010 -4.308.000 162.6%
2011 -5.085.000 15.28%
2012 -7.027.000 27.64%
2013 -16.042.000 56.2%
2014 -15.194.000 -5.58%
2015 -18.973.000 19.92%
2016 -13.151.000 -44.27%
2017 -7.403.000 -77.64%
2018 -6.545.000 -13.11%
2019 -10.487.000 37.59%
2020 -11.039.000 5%
2021 -6.559.000 -68.3%
2022 -16.265.000 59.67%
2023 -7.028.000 -131.43%
2023 -9.640.000 27.1%
2024 -6.340.000 -52.05%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

NovaBay Pharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 -211
2004 -560 62.32%
2005 -625 10.26%
2006 -809 22.87%
2007 -527 -53.8%
2008 -333 -57.96%
2009 105 417.14%
2010 -162 165.22%
2011 -173 6.4%
2012 -210 18.1%
2013 -368 42.78%
2014 -268 -37.45%
2015 -239 -12.18%
2016 -49 -385.71%
2017 -17 -206.25%
2018 -14 -23.08%
2019 -17 18.75%
2020 -11 -45.45%
2021 -5 -120%
2022 -10 50%
2023 -1 -900%
2023 -2 50%
2024 -5 60%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

NovaBay Pharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
2005 -3.353.000
2006 4.382.000 176.52%
2007 -6.934.000 163.2%
2008 -10.552.000 34.29%
2009 -2.379.000 -343.55%
2010 1.825.000 230.36%
2011 -3.261.000 155.96%
2012 -6.676.000 51.15%
2013 -13.110.000 49.08%
2014 -15.123.000 13.31%
2015 -18.682.000 19.05%
2016 -12.295.000 -51.95%
2017 -6.514.000 -88.75%
2018 -5.612.000 -16.07%
2019 -7.948.000 29.39%
2020 -4.747.000 -67.43%
2021 -9.244.000 48.65%
2022 -6.766.000 -36.62%
2023 -4.331.000 -56.22%
2023 -365.000 -1086.58%
2024 -676.000 46.01%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

NovaBay Pharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
2005 -3.230.000
2006 4.744.000 168.09%
2007 -6.271.000 175.65%
2008 -9.942.000 36.92%
2009 -1.648.000 -503.28%
2010 2.028.000 181.26%
2011 -3.142.000 164.54%
2012 -6.528.000 51.87%
2013 -12.969.000 49.66%
2014 -15.055.000 13.86%
2015 -18.559.000 18.88%
2016 -12.135.000 -52.94%
2017 -6.270.000 -93.54%
2018 -5.568.000 -12.61%
2019 -7.929.000 29.78%
2020 -4.721.000 -67.95%
2021 -9.192.000 48.64%
2022 -6.654.000 -38.14%
2023 -4.312.000 -54.31%
2023 -363.000 -1087.88%
2024 -674.000 46.14%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

NovaBay Pharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
2005 123.000
2006 362.000 66.02%
2007 663.000 45.4%
2008 610.000 -8.69%
2009 731.000 16.55%
2010 203.000 -260.1%
2011 119.000 -70.59%
2012 148.000 19.59%
2013 141.000 -4.96%
2014 68.000 -107.35%
2015 123.000 44.72%
2016 160.000 23.13%
2017 244.000 34.43%
2018 44.000 -454.55%
2019 19.000 -131.58%
2020 26.000 26.92%
2021 52.000 50%
2022 112.000 53.57%
2023 19.000 -489.47%
2023 2.000 -850%
2024 2.000 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

NovaBay Pharmaceuticals, Inc. Equity
Year Equity Growth
2003 802.000
2005 3.252.000 75.34%
2006 1.813.000 -79.37%
2007 14.320.000 87.34%
2008 7.345.000 -94.96%
2009 13.345.000 44.96%
2010 10.490.000 -27.22%
2011 9.344.000 -12.26%
2012 14.049.000 33.49%
2013 8.516.000 -64.97%
2014 1.848.000 -360.82%
2015 -5.098.000 136.25%
2016 7.101.000 171.79%
2017 2.594.000 -173.75%
2018 4.954.000 47.64%
2019 973.000 -409.15%
2020 12.318.000 92.1%
2021 10.171.000 -21.11%
2022 10.554.000 3.63%
2023 3.314.000 -218.47%
2023 7.037.000 52.91%
2024 -617.000 1240.52%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

NovaBay Pharmaceuticals, Inc. Assets
Year Assets Growth
2003 1.315.000
2005 3.562.000 63.08%
2006 11.866.000 69.98%
2007 23.922.000 50.4%
2008 13.969.000 -71.25%
2009 17.523.000 20.28%
2010 15.516.000 -12.94%
2011 15.963.000 2.8%
2012 19.235.000 17.01%
2013 15.650.000 -22.91%
2014 7.537.000 -107.64%
2015 5.077.000 -48.45%
2016 15.381.000 66.99%
2017 10.079.000 -52.6%
2018 9.361.000 -7.67%
2019 11.220.000 16.57%
2020 15.238.000 26.37%
2021 23.978.000 36.45%
2022 16.399.000 -46.22%
2023 9.034.000 -81.53%
2023 12.852.000 29.71%
2024 3.925.000 -227.44%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

NovaBay Pharmaceuticals, Inc. Liabilities
Year Liabilities Growth
2003 513.000
2005 310.000 -65.48%
2006 10.053.000 96.92%
2007 9.602.000 -4.7%
2008 6.624.000 -44.96%
2009 4.178.000 -58.54%
2010 5.026.000 16.87%
2011 6.619.000 24.07%
2012 5.186.000 -27.63%
2013 7.134.000 27.31%
2014 5.689.000 -25.4%
2015 10.175.000 44.09%
2016 8.280.000 -22.89%
2017 7.485.000 -10.62%
2018 4.407.000 -69.84%
2019 10.247.000 56.99%
2020 2.920.000 -250.92%
2021 13.807.000 78.85%
2022 5.845.000 -136.22%
2023 5.720.000 -2.19%
2023 5.815.000 1.63%
2024 4.542.000 -28.03%

NovaBay Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
10.4
Net Income per Share
-9.23
Price to Earning Ratio
-0.07x
Price To Sales Ratio
0.28x
POCF Ratio
-0.28
PFCF Ratio
-1.18
Price to Book Ratio
-1.28
EV to Sales
0.38
EV Over EBITDA
-1.03
EV to Operating CashFlow
-1.63
EV to FreeCashFlow
-1.62
Earnings Yield
-13.5
FreeCashFlow Yield
-0.85
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
10.53
Graham NetNet
-2.62

Income Statement Metrics

Net Income per Share
-9.23
Income Quality
0.27
ROE
-4.31
Return On Assets
-2.61
Return On Capital Employed
-2.37
Net Income per EBT
0.92
EBT Per Ebit
2.45
Ebit per Revenue
-0.4
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
0.53
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.61
Operating Profit Margin
-0.4
Pretax Profit Margin
-0.98
Net Profit Margin
-0.9

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-2.45
Free CashFlow per Share
-2.46
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0.06
Return on Invested Capital
-3.37
Return on Tangible Assets
-2.72
Days Sales Outstanding
16.62
Days Payables Outstanding
90.63
Days of Inventory on Hand
51.37
Receivables Turnover
21.96
Payables Turnover
4.03
Inventory Turnover
7.11
Capex per Share
0.01

Balance Sheet

Cash per Share
0,65
Book Value per Share
-0,53
Tangible Book Value per Share
-0.53
Shareholders Equity per Share
-0.53
Interest Debt per Share
2.37
Debt to Equity
-3.26
Debt to Assets
0.51
Net Debt to EBITDA
-0.28
Current Ratio
0.62
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-161000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
681500
Debt to Market Cap
0.6

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

NovaBay Pharmaceuticals, Inc. Dividends
Year Dividends Growth

NovaBay Pharmaceuticals, Inc. Profile

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

CEO
Mr. Justin M. Hall Esq.
Employee
24
Address
2000 Powell Street
EmeryVille, 94608

NovaBay Pharmaceuticals, Inc. Executives & BODs

NovaBay Pharmaceuticals, Inc. Executives & BODs
# Name Age
1 Mr. Justin M. Hall Esq.
President, Chief Executive Officer, General Counsel, Chief Compliance Officer, Corporate Secretary & Director
70
2 Mr. Tommy Law
Controller, Interim Chief Financial Officer & Treasurer
70

NovaBay Pharmaceuticals, Inc. Competitors